If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

21 Jul 2023 10:56

RNS Number : 8235G
MGC Pharmaceuticals Limited
21 July 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

AU000000MXC6

Issuer Name

MGC Pharmaceuticals Limited

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Miton UK MicroCap Trust plc

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

BNY (OCS) Nominees Limited

London

England

5. Date on which the threshold was crossed or reached

14-Jul-2023

6. Date on which Issuer notified

18-Jul-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.526895

0.000000

4.526895

176203028

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

AU000000MXC6

176203028

4.526895

Sub Total 8.A

176203028

4.526895%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

18/07/2023

13. Place Of Completion

Exeter, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUAVKROSUBURR
Date   Source Headline
6th Apr 202212:02 pmRNSNotification of ASX Market Announcement
5th Apr 20227:00 amRNSDistribution Partnership with Sciensus Rare
10th Mar 20229:10 amRNSJoint Company Secretary Retirement
4th Mar 20224:36 pmRNSDirector/PDMR Shareholding
1st Mar 202211:53 amRNSPrior Share Issues & Admission to Trading
1st Mar 20227:00 amRNSInterim Financial Report
22nd Feb 20228:08 amRNSDirector/PDMR Shareholding
16th Feb 20221:51 pmRNSResult of General Meeting
16th Feb 202212:15 pmRNSShare Issues in 2021
10th Feb 202210:30 amRNSIssue of New Shares Completed in 2021
3rd Feb 202210:42 amRNSDirector/PDMR Shareholding
31st Jan 202211:06 amRNSSecond Price Monitoring Extn
31st Jan 202211:01 amRNSPrice Monitoring Extension
31st Jan 20228:22 amRNSDecember Quarterly Activities Report and Cash Flow
14th Jan 20229:00 amRNSDispatch of General Meeting Documents
6th Jan 20227:00 amRNSImport approval for ArtemiC Rescue in India
20th Dec 20217:00 amRNSClinical Study on influence of ArtemiC Support®
8th Dec 20219:15 amRNSIssue of Shares
6th Dec 20219:30 amRNSPlacing Settlement
30th Nov 20217:00 amRNS£5.5m Capital Raising Completed
29th Nov 202110:06 amRNSDirector/PDMR Shareholding
25th Nov 20217:00 amRNSResult of AGM
24th Nov 20219:00 amRNSCompletion of $1m ArtemiC order to Swiss PharmaCan
24th Nov 20217:00 amRNSIssue of Shares & Extension of Convertible Note
24th Nov 20217:00 amRNSDirector/PDMR Shareholding
22nd Nov 20219:30 amRNSFull Cash Deposit Recieved for US Order of CimetrA
19th Nov 20218:31 amRNSAnnual General Meeting Webinar Information
16th Nov 202111:31 amRNSRelease of Shares from Voluntary Escrow
12th Nov 20219:30 amRNSNotification of ASX Market Announcement
2nd Nov 20217:00 amRNSMalta Production Facility Completion
1st Nov 20217:00 amRNSApproval For Global CimetrA™ Dose Finding Study
26th Oct 20217:00 amRNSSeptember 2021 Quarterly Report & Cash Flow
25th Oct 20211:49 pmRNSDispatch of Annual General Meeting Documents
12th Oct 20217:00 amRNSCimetrATM Investor Presentation
7th Oct 20219:18 amRNSDirector/PDMR Shareholding
6th Oct 20217:08 amRNSAMC USA Places a US$3M Purchase Order for CimetrA
6th Oct 20217:00 amRNSCompany Presentation October 2021
4th Oct 20219:29 amRNSDirector/PDMR Shareholding
30th Sep 20218:00 amRNSAnnual Financial Report
29th Sep 20217:00 amRNSAMC Holdings orders first 1000 units of CimetrA™
22nd Sep 20218:36 amRNSNotification of ASX Market Announcements
20th Sep 202111:03 amRNSDirector/PDMR Shareholding
20th Sep 202110:57 amRNSNotification of ASX Market Announcements
15th Sep 20217:04 amRNSArtemiC Update - Approval for sale in EU & Results
13th Sep 20213:43 pmRNSDirector/PDMR Shareholding
13th Sep 20217:00 amRNSLandmark UK Import Permit granted for CannEpil+
9th Sep 202111:45 amRNSNotification of ASX Market Announcements
9th Sep 202111:35 amRNSNotification of ASX Market Announcements
8th Sep 20219:05 amRNSSecond Price Monitoring Extn
8th Sep 20219:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.